We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rare Infection in Transplant Recipients Linked to Donors

By LabMedica International staff writers
Posted on 01 Jun 2017
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
The way in which heart and lung transplant recipients acquired a specific species of bacteria, Mycoplasma hominis, had been previously undefined, and the bacterium was difficult to test for and detect. Originally, this bacterium was considered to reside exclusively in, and be a potential pathogen of the area of the reproductive and urinary organs.

M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.

Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.

Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.

Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Clinical Chemistry System
P780

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more